Satsuma Pharmaceuticals Overview
- Year Founded
-
2016
- Status
-
Acquired/Merged
- Employees
-
16
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$30M
Satsuma Pharmaceuticals General Information
Description
Satsuma Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasal delivery device.
Contact Information
Website
www.satsumarx.com(Operating Subsidiary)
Corporate Office
- 4819 Emperor Boulevard
- Suite 340
- Durham, NC 27703
- United States
Corporate Office
- 4819 Emperor Boulevard
- Suite 340
- Durham, NC 27703
- United States
Satsuma Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 08-Jun-2023 | $30M | Completed | Clinical Trials - General | ||
| 5. PIPE | 31-Mar-2021 | Completed | Clinical Trials - General | |||
| 4. IPO | 13-Sep-2019 | Completed | Clinical Trials - General | |||
| 3. Early Stage VC (Series B) | 24-Apr-2019 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A) | 12-Feb-2018 | $12.1M | $12.1M | Completed | Startup | |
| 1. Accelerator/Incubator | Completed | Startup |
Satsuma Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
Satsuma Pharmaceuticals Comparisons
Industry
Financing
Details
Satsuma Pharmaceuticals Competitors (11)
One of Satsuma Pharmaceuticals’s 11 competitors is Heron Therapeutics, a Formerly VC-backed company based in Cary, NC.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Heron Therapeutics | Formerly VC-backed | Cary, NC | ||||
| Voyager Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| OptiNose | Private Equity-Backed | PA | ||||
| IPI Legacy Liquidation | Formerly VC-backed | Seattle, WA | ||||
| Centrexion Therapeutics | Venture Capital-Backed | Boston, MA |
Satsuma Pharmaceuticals Patents
Satsuma Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3122396-A1 | Compositions, devices, and methods for treating or preventing headaches | Active | 11-Dec-2018 | ||
| EP-3893877-A1 | Compositions, devices, and methods for treating or preventing headaches | Pending | 11-Dec-2018 | ||
| EP-3893877-A4 | Compositions, devices, and methods for treating or preventing headaches | Pending | 11-Dec-2018 | ||
| GB-2581431-A | Compositions, devices, and methods for treating or preventing headaches | Inactive | 11-Dec-2018 | ||
| US-10758532-B2 | Compositions, devices, and methods for treating or preventing headaches | Active | 11-Dec-2018 | A61K31/48 |
Satsuma Pharmaceuticals Signals
Satsuma Pharmaceuticals Former Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CAM Capital | Asset Manager | Minority | ||
| Citadel Enterprise Americas | Hedge Fund | Minority | ||
| Commodore Capital | Venture Capital | Minority | ||
| Cormorant Asset Management | PE/Buyout | Minority | ||
| Eventide Asset Management | Venture Capital | Minority |
Satsuma Pharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Satsuma Pharmaceuticals FAQs
-
When was Satsuma Pharmaceuticals founded?
Satsuma Pharmaceuticals was founded in 2016.
-
Where is Satsuma Pharmaceuticals headquartered?
Satsuma Pharmaceuticals is headquartered in Durham, NC.
-
What is the size of Satsuma Pharmaceuticals?
Satsuma Pharmaceuticals has 16 total employees.
-
What industry is Satsuma Pharmaceuticals in?
Satsuma Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Satsuma Pharmaceuticals a private or public company?
Satsuma Pharmaceuticals is a Private company.
-
What is the current valuation of Satsuma Pharmaceuticals?
The current valuation of Satsuma Pharmaceuticals is .
-
What is Satsuma Pharmaceuticals’s current revenue?
The current revenue for Satsuma Pharmaceuticals is .
-
How much funding has Satsuma Pharmaceuticals raised over time?
Satsuma Pharmaceuticals has raised $237M.
-
Who are Satsuma Pharmaceuticals’s investors?
CAM Capital, Citadel Enterprise Americas, Commodore Capital, Cormorant Asset Management, and Eventide Asset Management are 5 of 15 investors who have invested in Satsuma Pharmaceuticals.
-
Who are Satsuma Pharmaceuticals’s competitors?
Heron Therapeutics, Voyager Therapeutics, OptiNose, IPI Legacy Liquidation, and Centrexion Therapeutics are some of the 11 competitors of Satsuma Pharmaceuticals.
-
When was Satsuma Pharmaceuticals acquired?
Satsuma Pharmaceuticals was acquired on 08-Jun-2023.
-
Who acquired Satsuma Pharmaceuticals?
Satsuma Pharmaceuticals was acquired by Shin Nippon Biomedical Laboratories.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process